Zacks.com on MSN7 天
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
Alnylam Pharmaceuticals ALNY presented new data from its early-stage study of nucresiran (formerly ALN-TTRsc04) for treating ...